Hemolytic Anemia
10
0
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects
A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia
Study of Acquired Hemolytic Anemia in Adult Hospitalized Patients
Long Term Effects of Erythrocyte Lysis
Immunoglobulin Dosage and Administration Form in CIDP and MMN
Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Combination Drug Therapy for Patients With Hepatitis C